Get the Weekly Intelligence Brief — top committee picks every Sunday.
NASDAQ · STOCK

Charles River Laboratories

CRL Healthcare Unknown Updated July 31, 2026
$232.67
52W $144.26 – $242.73
52/100
$11.20B
-62.0
1.40
AI Committee Verdict
Watch
Conviction: Unanimous · 100% agreement · 6 analysts
+3.0%
-5.0%
0.61:1
Unanimous

Is CRL Bullish or Bearish?

Mixed. Innellis AI committee rates Charles River Laboratories (CRL) Watch with a composite score of 52/100 , based on 6 analysts with 100% agreement. Last updated July 31, 2026.

What Would Change This View

Upgrade to Buy
Requires a committee score of 60.0 — +7.55 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Reduce
Requires the score to fall below 40.0 — -12.45 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

The committee sees neither a compelling opportunity nor a clear risk at this stage. Conditions remain neutral — patience is warranted.

Bull & Bear Case

Bull Case
  • 4 consecutive earnings beats -- consistent execution — Growth
  • Price structure making higher highs and higher lows — Technical
  • Trend and market structure agree -- coherent bullish picture — Technical
  • Market regime is bullish (Bull market -- normal position sizing) — Macro
  • Beta of 1.37 means this name should amplify a favorable market regime — Macro
Bear Case
  • ROE of only -5.7% -- cheap may mean cheap for a reason — Value
  • Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
  • MACD histogram negative -- bearish momentum — Technical
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of July 31, 2026
Overall Committee Score
52/100
Agreement
100%
Analysts
6
Conviction
Unanimous
Sector Rank
Top 72%
of 93 Healthcare peers
Value Analyst neutral
42 / 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
− ROE of only -5.7% -- cheap may mean cheap for a reason
Growth Analyst neutral
52 / 100 · High confidence
Moderate growth -- present but not remarkable
+ 4 consecutive earnings beats -- consistent execution
− Growth rate is decelerating quarter over quarter -- the trend line matters more than the level
Technical Analyst neutral
58 / 100 · High confidence
Mixed or range-bound price action
+ Price structure making higher highs and higher lows
− MACD histogram negative -- bearish momentum
Macro Analyst neutral
58 / 100 · Moderate confidence
Macro backdrop is mixed or neutral -- not a strong tailwind or headwind either way
+ Market regime is bullish (Bull market -- normal position sizing)
News Analyst neutral
60 / 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager neutral
45 / 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 2744.14)
Open Full Terminal →

Investment Thesis Evolution

Committee score moved marginally from 53.7 to 52.5.

Analyst-level changes:
  • Macro Analyst: stance bullish->neutral; score 65->58 (-8); +2 bullish signal(s).
  • Portfolio Manager: +2 bearish signal(s).

Comparing 2026-07-30 to 2026-07-31 (1 day apart).

Technical Analysis

RSI (14)
57.0
Neutral
MACD Histogram
-0.757
Bearish Momentum
Trend Direction
Uptrend
Weekly: Sideways
Market Structure
Hh Hl
Support
$221.07
Resistance
$239.73
Bollinger %B
0.67
Inside Bands
Price vs Moving Averages
EMA 9
$230.85 Above
EMA 21
$225.21 Above
EMA 50
$210.36 Above
EMA 200
$187.78 Above

Fundamental Analysis

Valuation
88
Growth
57
Profitability
0
Financial Health
60
Cash Flow
37
Valuation
P/E Ratio -62.0×
P/B Ratio 3.87×
PEG Ratio 0.62
Dividend Yield 0.00%
52W High $242.73
52W Low $144.26
Quality & Growth
ROE -4.6%
ROA -2.0%
Gross Margin 31.9%
Operating Margin 11.8%
Revenue Growth YoY
Debt / Equity 1.04
AI Fundamental Assessment
P/E ratio of -62.0 (inexpensive relative to a 15-40x range); Price-to-book of 3.9x; PEG ratio of 0.6 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -0.0%; Return on assets of -0.0%; Net margin of -0.0%; Gross margin of 0.3%; Current ratio of 1.36 (tight short-term liquidity); Debt-to-equity of 1.04; Free cash flow margin of 0.6% (thin cash generation); Free cash flow per share is positive (7.99); Most recent quarter beat estimates by 5.0%; 4 consecutive earnings beats; EPS growth decelerating (-1.6% -> -13.8% QoQ); Analyst estimates falling over recent quarters
Get the Full CRL Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →

Explore CRL Further

📈 Rating History 💰 Earnings 📰 Recent Events 🔄 What Changed 📖 Thesis Evolution 🔍 Similar Stocks
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime